How “Humane” Is Your Endpoint?—Refining the Science-Driven Approach for Termination of Animal Studies of Chronic Infection

1. RussellWMSBurchRL 1959 The principles of humane experimental technique London: Methuen & Co. Ltd.

2. ILAR 2000 Humane endpoints for animals used in biomedical research and testing. ILAR Journal 41

3. NRC 2009 Recognition and alleviation of pain in laboratory animals. Washington (D.C.) National Academies Press

4. GuittinPDecelleT 2002 Future improvements and implementation of animal care practices within the animal testing regulatory environment. ILAR J 43 Suppl S80 S84

5. OECD 2000 Guidance document on the recognition, assessment and use of clinical signs as humane endpoints for experiemental animal used in safety evaluation. Paris Organisation for Economic Co-operation and Development

6. TothLA 2000 Defining the moribund condition as an experimental endpoint for animal research. ILAR J 41 72 79

7. ChackerianAABeharSM 2003 Susceptibility to Mycobacterium tuberculosis: lessons from inbred strains of mice. Tuberculosis (Edinburgh, Scotland) 83 279 285

8. MedinaENorthRJ 1998 Resistance ranking of some common inbred mouse strains to Mycobacterium tuberculosis and relationship to major histocompatibility complex haplotype and Nramp1 genotype. Immunology 93 270 274

9. KondratievaELogunovaNMajorovKAverbakhMAptA 2010 Host genetics in granuloma formation: human-like lung pathology in mice with reciprocal genetic susceptibility to M. tuberculosis and M. avium. PLoS ONE 5 e10515 doi:10.1371/journal.pone.0010515

10. YuanRTsaihSWPetkovaSBde EvsikovaCMXingSQ 2009 Aging in inbred strains of mice: study design and interim report on median lifespans and circulating IGF1 levels. Aging Cell 8 277 287

11. SrivastavaSAyyagariADholeTNKrishnaniNNyatiKK 2008 Progression of chronic pulmonary tuberculosis in mice intravenously infected with ethambutol resistant Mycobacterium tuberculosis. Indian J Med Microbi 26 342 348

12. NorthRJJungYJ 2004 Immunity to tuberculosis. Annu Rev Immunol 22 599 623

13. RookGAWHernandezPandoR 1997 Pathogenetic role, in human and murine tuberculosis, of changes in the peripheral metabolism of glucocorticoids and antiglucocorticoids. Psychoneuroendocrino 22 S109 S113

14. BlochH 1950 Studies on the virulence of tubercle bacilli - the relationship of the physiological state of the organisms to their pathogenicity. J Exp Med 92 507 526

15. MenchJ 1999 Defining endpoints: the role of animal care committees. MortonCFMHaDB Humane endpoints in animals experiments for biomedical research London Royal Society of Medicine Press 133 138

16. MortonDB 2006 Ethical issues in the use of animal models of infection and some practical refinements. FriedmanHSpecterSBendinelliM In vivo models of HIV disease and control 405 424 Springer US

17. OlfertEDGodsonDL 2000 Humane endpoints for infectious disease animal models. ILAR J 41 99 104

18. LyadovaIVTsiganovENKapinaMAShepelkovaGSSosunovVV 2010 In mice, tuberculosis progression is associated with intensive inflammatory response and the accumulation of Gr-1 cells in the lungs. PLoS ONE 5 e10469 doi:10.1371/journal.pone.0010469

19. NikonenkoBVAverbakhMMLavebrattCSchurrEAptAS 2000 Comparative analysis of mycobacterial infections in susceptible I/St and resistant A/Sn inbred mice. Tuber Lung Dis 80 15 25

20. RomanoMD'SouzaSAdnetP-YLaaliRJurionF 2006 Priming but not boosting with plasmid DNA encoding mycolyl-transferase Ag85A from Mycobacterium tuberculosis increases the survival time of Mycobacterium bovis BCG vaccinated mice against low dose intravenous challenge with M. tuberculosis H37Rv. Vaccine 24 3353

21. StewartGRNewtonSMWilkinsonKAHumphreysIRMurphyHN 2005 The stress-responsive chaperone alpha-crystallin 2 is required for pathogenesis of Mycobacterium tuberculosis. Mol Microbiol 55 1127 1137

22. BigbeeCLGonchoroffDGVratsanosGNadlerSGHaggertyHG 2007 Abatacept treatment does not exacerbate chronic Mycobacterium tuberculosis infection in mice. Arthritis Rheum 56 2557 2565

23. LavebrattCAptASNikonenkoBVSchallingMSchurrE 1999 Severity of tuberculosis in mice is linked to distal chromosome 3 and proximal chromosome 9. J Infect Dis 180 150 155

24. SánchezFRadaevaTVNikonenkoBVPerssonA-SSengulS 2003 Multigenic control of disease severity after virulent Mycobacterium tuberculosis infection in mice. Infect Immun 71 126 131

25. NikonenkoBVSamalaREinckLNacyCA 2004 Rapid, simple in vivo screen for new drugs active against Mycobacterium tuberculosis. Antimicrob Agents Chemother 48 4550 4555

26. SpohnGGulerRJohansenPKellerIJacobsM 2007 A virus-like particle-based vaccine selectively targeting soluble TNF-alpha protects from arthritis without inducing reactivation of latent tuberculosis. J Immunol 178 7450 7457

27. TriccasJAShklovskayaESprattJRyanAAPalendiraU 2007 Effects of DNA- and Mycobacterium bovis BCG-based delivery of the Flt3 ligand on protective immunity to Mycobacterium tuberculosis. Infect Immun 75 5368 5375

28. UrdahlKBLiggittDBevanMJ 2003 CD8(+) T cells accumulate in the lungs of Mycobacterium tuberculosis-infected Kb-/-Db-/- mice, but provide minimal protection. J Immunol 170 1987 1994

29. HolscherCHolscherARuckerlDYoshimotoTYoshidaH 2005 The IL-27 receptor chain WSX-1 differentially regulates antibacterial immunity and survival during experimental tuberculosis. J Immunol 174 3534 3544

30. KapinaMAShepelkovaGSMischenkoVVSaylesPBogachevaP 2007 CD27(low) CD4 T lymphocytes that accumulate in the mouse lungs during mycobacterial infection differentiate from CD27(high) precursors in situ, produce IFN-gamma, and protect the host against tuberculosis infection. J Immunol 178 976 985

31. KortWJHekking-WeijmaJMTenkateMTSormVVanStrikR 1998 A microchip implant system as a method to determine body temperature of terminally ill rats and mice. Lab Anim 32 260 269

32. SoothillJSMortonDBAhmadA 1992 The HID50 (hypothermia-inducing dose 50): an alternative to the LD50 for measurement of bacterial virulence. Int J Exp Pathol 73 95 98

33. WongJPSaravolacEGClementJGNagataLP 1997 Development of a murine hypothermia model for study of respiratory tract influenza virus infection. Lab Anim Sci 47 143 147

34. BastDJYueMChenXBellDDresserL 2004 Novel murine model of pneumococcal pneumonia: use of temperature as a measure of disease severity to compare the efficacies of moxifloxacin and levofloxacin. Antimicrob Agents Chemother 48 3343 3348

35. WarnPABramptonMWSharpAMorrisseyGSteelN 2003 Infrared body temperature measurement of mice as an early predictor of death in experimental fungal infections. Lab Anim 37 126 131

36. VlachKDBolesJWStilesBG 2000 Telemetric evaluation of body temperature and physical activity as predictors of mortality in a murine model of staphylococcal enterotoxic shock. Comparative Med 50 160 166

37. VerhoevenDTeijaroJRFarberDL 2009 Pulse-oximetry accurately predicts lung pathology and the immune response during influenza infection. Virology 390 151 156

38. SchaecherKKumarSYadavaAVaheyMOckenhouseCF 2005 Genome-wide expression profiling in malaria infection reveals transcriptional changes associated with lethal and nonlethal outcomes. Infect Immun 73 6091 6100

39. YuYClippingerAJAlwineJC 2011 Viral effects on metabolism: changes in glucose and glutamine utilization during human cytomegalovirus infection. Trends Microbiol 19 360 367

40. BeamerGLFlahertyDKVesoskyBTurnerJ 2008 Peripheral blood gamma interferon release assays predict lung responses and Mycobacterium tuberculosis disease outcome in mice. Clin Vaccine Immunol 15 474 483

41. JamilBShahidFHasanZNasirNRazzakiT 2007 Interferon[gamma]/IL10 ratio defines the disease severity in pulmonary and extra pulmonary tuberculosis. Tuberculosis 87 279 287

42. MillingtonKAInnesJAHackforthSHinksTSCDeeksJJ 2007 Dynamic relationship between IFN-γ and IL-2 profile of Mycobacterium tuberculosis-specific T cells and antigen load. J Immunol 178 5217 5226

43. BerryMPRGrahamCMMcNabFWXuZBlochSAA 2010 An interferon-inducible neutrophil-driven blood transcriptional signature in human tuberculosis. Nature 466 973 977

44. DemersGGriffinGDe VroeyGHaywoodJRZurloJ 2006 Harmonization of animal care and use guidance. Science 312 700 701